Our study establishes in a large, well‐defined clinical trial population pretreatment serum albumin levels as a cheap and easily available independent prognostic factor for survival in elderly patients with aggressive B‐cell lymphoma in the R‐CHOP era. This evidence concerns the gene ALB and B-cell non-Hodgkin lymphoma.